SCHEMBL564672

SCHEMBL564672

C=Cc1cc(Oc2ccc(S(C)(=O)=O)nc2)ccc1[N+](=O)[O-]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
HTT P42858 1/20 0.36
PIN1 Q13526 2/20 0.33
CYP19A1 P11511 1/20 0.33
MAPT P10636 3/20 0.33
LMNA P02545 1/20 0.33
BACE1 P56817 1/20 0.32
NFE2L2 Q16236 1/20 0.32
HSP90AA1 P07900 1/20 0.32
CXCR5 P32302 1/20 0.32
APLNR P35414 1/20 0.32
RAB9A P51151 1/20 0.32
CCR6 P51684 1/20 0.32
GFER P55789 1/20 0.32
KMT2A Q03164 1/20 0.32
ERN1 O75460 1/20 0.31
PIK3CD O00329 1/20 0.31
PIP5K1C O60331 1/20 0.31
PIK3CB P42338 1/20 0.31
PI4KA P42356 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564681 0.83 MAPT (0.43) ALDH1A1HTTMAPTLMNARAB9A
SCHEMBL2645604 0.76 MAPT (0.41) ALDH1A1HTTPIN1MAPTLMNA
SCHEMBL563690 0.76 HSPB1 (0.49) ALDH1A1HTTMAPTLMNAHSP90AA1
SCHEMBL1039005 0.75 CYP19A1 (0.43) PIN1CYP19A1MAPTRAB9AKMT2A
SCHEMBL564333 0.73 GCK (0.39) ALDH1A1HTTCYP19A1MAPTKMT2A
SCHEMBL16953181 0.72 BACE1 (0.52) ALDH1A1HTTCYP19A1MAPTLMNA
SCHEMBL16953824 0.72 MAPT (0.61) ALDH1A1HTTMAPTLMNARAB9A
SCHEMBL3552351 0.71 MAPT (0.40) ALDH1A1HTTCYP19A1MAPTLMNA
SCHEMBL2646047 0.70 MAPT (0.39) ALDH1A1HTTPIN1MAPTLMNA
SCHEMBL11849513 0.69 ALDH1A1 (0.43) ALDH1A1HTTMAPTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557805-B2 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-15 US disclosed
US-20120035163-A1 NOVEL FUSED RING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2012-02-09 US disclosed
EP-2371826-A1 NOVEL FUSED RING COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035163-A1 NOVEL FUSED RING COMPOUND AND USE THEREOF GPR119, GCKR, SLC5A1 ALDH1A1 351/4885HTT 3223/4885PIN1 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.